Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Lancet
    April 2024
  1. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    >> Share

  2. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    >> Share

    March 2024
  3. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    >> Share

  4. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    >> Share

  5. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    >> Share

    December 2023
  6. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    >> Share

  7. MANN GB, Skandarajah AR, Zdenkowski N, Hughes J, et al
    Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
    Lancet. 2023 Dec 5:S0140-6736(23)02476-5. doi: 10.1016/S0140-6736(23)02476.
    >> Share

  8. BRAUNSTEIN LZ
    Optimising adjuvant breast radiotherapy via preoperative imaging.
    Lancet. 2023 Dec 5:S0140-6736(23)02698-3. doi: 10.1016/S0140-6736(23)02698.
    >> Share

    November 2023

  9. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
    Lancet. 2023 Nov 3:S0140-6736(23)01082-6. doi: 10.1016/S0140-6736(23)01082.
    >> Share

  10. LEVINE MN
    Effective and safe regional node irradiation in early breast cancer.
    Lancet. 2023 Nov 3:S0140-6736(23)01614-8. doi: 10.1016/S0140-6736(23)01614.
    >> Share

  11. ZAMAN M, de Vale ML, Coultas C, Goff L, et al
    Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.
    Lancet. 2023;402 Suppl 1:S96.
    >> Share

  12. HUNTLEY C, Torr B, Sud A, Houlston RS, et al
    The impact of risk stratification by polygenic risk and age on breast cancer screening in women aged 40-49 years: a modelling study.
    Lancet. 2023;402 Suppl 1:S54.
    >> Share

  13. ACHARYA A, Darzi A, Judah G
    An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S17.
    >> Share

    August 2023
  14. LOIBL S, Holtschmidt J
    Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some?
    Lancet. 2023 Aug 23:S0140-6736(23)01783-X. doi: 10.1016/S0140-6736(23)01783.
    >> Share

  15. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Aug 23:S0140-6736(23)01245-X. doi: 10.1016/S0140-6736(23)01245.
    >> Share

    June 2023
  16. COLES CE, Haviland JS, Kirby AM, Griffin CL, et al
    Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
    Lancet. 2023 Jun 8:S0140-6736(23)00619-0. doi: 10.1016/S0140-6736(23)00619.
    >> Share

    April 2023
  17. ANDRE F, Hee Park Y, Kim SB, Takano T, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Apr 19:S0140-6736(23)00725-0. doi: 10.1016/S0140-6736(23)00725.
    >> Share

  18. CHUMSRI S
    Advancing outcomes of metastatic HER2-positive breast cancer.
    Lancet. 2023 Apr 19:S0140-6736(23)00805-X. doi: 10.1016/S0140-6736(23)00805.
    >> Share


  19. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    Lancet. 2023;401:1277-1292.
    >> Share

  20. SHEN SJ, Liu CM
    Chemotherapy for early-stage breast cancer: the more the better?
    Lancet. 2023;401:1243-1245.
    >> Share

    January 2023
  21. CHUA BH, Link EK, Kunkler IH, Olivotto IA, et al
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
    Lancet. 2023;401:24.
    >> Share

  22. MULLIEZ T, De Ridder M
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
    Lancet. 2023;401:23-24.
    >> Share

    December 2022
  23. RASSY E, Delaloge S
    A second-generation antibody-drug conjugate to treat HER2-positive breast cancer.
    Lancet. 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.
    >> Share

  24. HURVITZ SA, Hegg R, Chung WP, Im SA, et al
    Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420.
    >> Share

    November 2022
  25. VRSELJA A, Latifi A, Baber RJ, Stuckey BGA, et al
    Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1704-1711.
    >> Share

  26. CRANDALL CJ, Ganz PA
    Phase 2 data on a new treatment for hot flushes in women with breast cancer.
    Lancet. 2022;400:1659-1661.
    >> Share

    August 2022
  27. CHUA BH, Link EK, Kunkler IH, Whelan TJ, et al
    Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
    Lancet. 2022;400:431-440.
    >> Share

  28. COLES CE, Chatterjee S, Jagsi R, Kirby AM, et al
    Breast radiotherapy for ductal carcinoma in situ: could less be more?
    Lancet. 2022;400:408-410.
    >> Share

    February 2022
  29. COLES CE, Anderson BO, Cameron D, Cardoso F, et al
    The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00184.
    >> Share

    January 2021

  30. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
    Lancet. 2021;397:387-397.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016